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Abstract
The Consensus Group deliberated on a number of questions concerning urine and stone analysis over a period of months, 
and then met to develop consensus. The Group concluded that analyses of urine and stones should be routine in the diagnosis 
and treatment of urinary stone diseases. At present, the 24-h urine is the most useful type of urine collection, and accepted 
methods for analysis are described. Patient education is also important for obtaining a proper urine sample. Graphical methods 
for reporting urine analysis results can be helpful both for the physician and for educating the patient as to proper dietary 
changes that could be beneficial. Proper analysis of stones is also essential for diagnosis and management of patients. The 
Consensus Group also agreed that research has shown that evaluation of urinary crystals could be very valuable, but the 
Group also recognizes that existing methods for assessment of crystalluria do not allow this to be part of stone treatment in 
many places.
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Introduction
The use of urine analysis as a guide to the diagnosis and 
treatment of kidney stones is recommended for at least some 
stone formers in all of the published international guidelines 
[1–4] (see Supplemental Table 1), but data suggest it is not 
generally utilized as widely as has been recommended. For 
example, a recent study of a large cohort within the United 
States (US) Veterans Affairs Health Care System found that 
fewer than 1-in-6 stone forming patients had undergone 24-h 
urine testing that would have been relevant to managing their 
urinary stone disease [5]. A possible interpretation of this 
low utilization of urine data is that physicians in the US are 
unconvinced that urine testing is valuable and cost-effective 
[6–8].
In the UK, most health authorities have abandoned the 
routine biochemical screening of stone patients to save 
money in favour of managing kidney stone patients solely 
through the urological removal or disintegration of their 
stones. This approach, in itself, does not “cure” the patients’ 
underlying risk of forming further stones. Furthermore, in 
general, no preventative treatment is instituted and so most 
patients return with further stones at a later date. It has been 
shown that this strategy actually costs more than would be 
the case if proper biochemical screening were to be insti-
tuted thereby resulting in a reduction in stone recurrence [9].
In contrast, within specialist stone centres for the treat-
ment of stone patients in Europe, the use of urine analysis 
for patient management is relatively uniform, with a recent 
survey showing that 96% of stone centres perform 24-h 
urine analyses as part of both initial and follow-up visits for 
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patients [10]. However, these specialist stone centres did not 
agree on the best methods for collection and analysis of a 
24-h urine specimen, and only 3 of the 24 stone centres that 
were surveyed commented that they used any calculation 
of the supersaturation levels of urinary salts and acids to 
assess their patients’ risks of forming further stones. Thus, 
even in health centres that specialize in the management of 
stone patients, there exists some uncertainty about how urine 
analyses should be performed and how the data should be 
interpreted.
A lack of uniformity also exists regarding methods of 
stone analysis, which is essential to the interpretation of 
urine analyses [11]. In the recent survey of European stone 
centres, 21% of the centres reported using only wet chemi-
cal, rather than spectroscopic methods for stone analysis 
[10], even though the use of chemical analysis has repeatedly 
been shown to result in serious errors that can lead to incor-
rect clinical conclusions [12, 13]. Finally, the identification 
of crystals in urine has not gained much traction as an aid 
to diagnosing and managing the stone forming patient, even 
though some researchers suggest that the disappearance of 
crystalluria is the best evidence that clinical management 
has been effective in reducing the risk of stone recurrence 
[14, 15].
The purpose of the convocation of the  4th International 
Meeting of the Menarini Foundation on Nephrolithiasis was 
to address these issues and to seek the consensus of an inter-
national Group of experts who specialize in various aspects 
of the use of urine, stone, and crystalluria analyses for treat-
ing stone patients. The Group worked to develop consensus 
on general topics (such as the value of urine analysis for 
treating stone forming patients) and on specific issues (such 
as how a specimen should be collected and analysed). The 
Group also sought to identify areas of study that would be 
especially fruitful for improving the scientific grounding of 
these practices.
Brief of the Consensus Group
The brief which was assigned to the Group by the Meeting’s 
organizers was: (1) to assess the current evidence for the 
use of urine analysis in the treatment of nephrolithiasis and 
to recommend best practice thereof; (2) to specify practi-
cal recommendations for the optimum collection of urine 
specimens and what variables should be measured in the 
specimens; (3) to identify the most suitable methods for 
measuring urine properties and constituents, what can be 
measured at home, what supersaturation and risk indices 
should be calculated, and how the results should be commu-
nicated to the referring physician and to the patient, and (4) 
to recommend optimum methods for the analysis of stones 
and crystals passed in urine.
The Group initially performed its work by means of elec-
tronic communication over a period of 5 months prior to 
Meeting in June 2019 in Verona, where it sought to reach a 
consensus. This document provides a summary of the con-
clusions of the Group.
References used
This document does not provide an exhaustive listing of all 
relevant research papers in the field. Instead, the works cited 
here have been selected as being the most appropriate for 
achieving consensus. All provide useful entry points into 
each subject area. However, an effort was made to ensure 
that no significant paper was ignored in the deliberations of 
the Consensus Group. This effort included solicitation of 
important papers from each of the members of the Group, 
followed by an appropriately extensive subject search using 
PubMed. Some key papers were also searched forward to 
look for citing articles using Web of Science (Clarivate).
Q1. What is the value of collecting urine 
samples from patients with kidney stones?
The process of crystallization in urine is complex, but urine 
analysis allows identification of the potential key chemi-
cal factors which are thought to lead to the precipitation of 
minerals that form stones. Armed with such information, 
physicians can institute appropriate interventions to alter 
these factors with a view to reducing the risk of further stone 
formation.
Treatment regimens such as specific dietary recommen-
dations (for example, to manage hypercalciuria and mild 
hyperoxaluria [16]), or administration of medications such 
as citrate (to increase pH and citrate in urine), thiazides (to 
decrease hypercalciuria), or allopurinol (to decrease hyperu-
ricosuria) are generally not implemented without prior urine 
analysis to identify the underlying pathological conditions 
concerned. Moreover, most physicians who prescribe such 
medications want to follow up their patients with repeat 
urine analysis to ensure that the patient is complying with 
treatment and that the medication is having the desired 
effect. Urine analysis is, therefore, crucial for directing the 
clinician towards suitable treatment and for following up the 
patient over time.
Although it might be possible for a physician to prescribe 
medications such as citrate, thiazides, or allopurinol in an 
empiric manner, and without urine analysis results [7], this 
is not common practice. A recent study of 130,489 stone 
patients in the US veterans system showed that only a minor-
ity of patients (13%) underwent a 24-h urine workup, but 
that this minority was more likely to be prescribed citrate, 
thiazide, or allopurinol than were the stone formers who 
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were not requested to collect a 24-h urine [17]. Importantly, 
their data also showed that prescription of these medica-
tions followed logically from the results of the patients’ 
24-h urines. Thus, physicians treating these stone patients 
were more likely to prescribe medication when the urine 
analysis data pointed to a specific need in the patient (e.g., 
to reduce hypercalciuria). Our consensus is that this is a 
rational approach, and that most physicians would not want 
to commit a patient to a medication without prior evidence 
from urine analysis. Indeed, a recent paper has shown that a 
decline in supersaturation values for calcium oxalate (CaOx) 
and in 24-h urine excretion of citrate, potassium and mag-
nesium with treatment were associated with longer periods 
without recurrence [18]. The Consensus Group recognized 
that more studies, such as this one, would be helpful in 
establishing the value of therapy driven by urine analysis 
in stone patients.
Urine analysis also forms part of the work-up of a stone-
forming patient for the identification of diseases predispos-
ing to or associated with nephrolithiasis. These conditions 
include primary hyperparathyroidism, primary hyperoxalu-
ria, enteric hyperoxaluria, cystinuria, and distal renal tubular 
acidosis. The percentage of stone formers who have one of 
these conditions is not large, but recognizing these diseases 
is essential for proper treatment, and urine analysis is cer-
tainly part of that process.
The assessment of a patient’s diet to identify potential 
predisposing factors is another extremely important benefit 
which clinicians can derive from analysis of urine. This 
aspect is discussed in several sections which appear later 
in this document.
It was recognized by the Consensus Group that in most 
countries, detailed analysis of urine samples from stone 
formers tends to be limited to specialist laboratories and 
practices. The Group agreed that transfer of basic skills to 
general practitioners could benefit huge numbers of patients 
worldwide.
Consensus on Q1
The consensus in the Group was that analysis of urine sam-
ples is essential for the meaningful management of stone 
formers. The Group recommends that urine analysis needs 
to be performed in conjunction with metabolic studies, stone 
analysis and dietary assessment.
Q2. What type of urine collection is best 
for assessing a patient’s risk of forming stones: 
a 24‑h urine, or some other type of collection?
Numerous reports in the literature on patients with urolithi-
asis refer to results of analysis of 24-h urine composition. 
An overwhelming number have shown that 24-h urinary 
risk factors for stone-formation are more frequently abnor-
mal in stone forming patients than in normal controls [7, 
19–21]. Reports also show that 24-h abnormalities provide 
useful information to help understand the underlying cause 
of stones in a given patient as well as for targeting changes 
in urine composition that should reduce his/her risk of 
stone recurrence. Both the American Urological Associa-
tion (AUA) and the European Association of Urology (EAU) 
in their guidelines recommend 24-h urine samples as the 
standard procedure for evaluation at least for calcium stone 
formers [1, 2]. In general, 24-h urine supersaturation levels 
may be used to predict the likelihood that a person is a stone 
former [22, 23].
Yet, as mentioned in the Introduction, remarkably few 
stone patients in the US are evaluated using 24-h urine data. 
A recent study of a very large cohort showed that patients 
who did not complete a 24-h urine study (87% of 130,489 
patients, all of whom were within a system that would pay 
for their 24-h urine testing) were less likely to receive medi-
cations that are thought to reduce the risk for stone recur-
rence such as thiazides, alkali, citrate or allopurinol. Those 
who did collect a 24-h urine were prescribed medication that 
was clearly linked to the results of their 24-h urine analyses 
[17]. This points to the practical value of 24-h urine testing 
in providing the physician with data to prompt and guide 
the prescription of appropriate dietary advice or medication.
Most of the participating experts expressed their belief 
that 24-h urine analysis is essential for diagnosing and fol-
lowing up patients with calcium-containing stones, for the 
appropriate prescription of medication to reduce stone recur-
rence, for advising patients on dietary adjustments, and for 
verifying (and encouraging) patient compliance. Even in 
those few cases in which spot urine could suffice for the 
diagnosis (i.e., cystinuria or primary hyperoxaluria) 24-h 
urine collections are essential for monitoring not only the 
effects of treatment on urine composition, but also on com-
pliance to the recommendation to increase water intake.
However, the efficacy of monitoring 24-h urine analysis 
during follow up with concomitant modification of dietary 
advice and drug treatment culminating in a decrease in stone 
recurrence is not established. Ferraro et al. [18] have investi-
gated this issue using a post-hoc analysis of the Borghi trial 
[24]. Due to the experimental design only very short-term 
variations (1 week) were considered. A prospective, rand-
omized trial has been conducted to compare recurrence in 
patients whose dietary recommendations were made with 
and without tests that included 24-h urine analysis [25], and 
the results of this trial support the value of 24-h urine test-
ing in reducing stone recurrence. However, more long-term, 
randomized control trials involving large numbers of stone 
patients are needed to establish the actual value of 24-h urine 
testing in preventing stone recurrence.
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The Group agreed that spot urines (including morning 
fasting urines) or other urine collections over part of a day 
can be valuable, too, but there are too few studies to iden-
tify best practice for urine analysis outside of the standard 
24-h collection. In view of the well-known diurnal varia-
tion of urine composition in calcium stone forming patients 
[26–29], it seems certain that analysis of urine at specific 
times of day could be even more informative than the com-
prehensive 24-h urine. This is important, because in some 
patients (such as children) obtaining a 24-h urine speci-
men is impractical. A recent paper has suggested that an 
afternoon collection of urine in children may substitute in 
some ways for a 24-h urine specimen [30]. In adults, there 
is evidence of variation among individuals in their diurnal 
patterns of urine composition [29], which complicates this 
approach. However, a recent proof-of-concept study on 
healthy volunteers has suggested that it might be rational to 
investigate specific timed urine collections according to the 
stone type (e.g., 8 pm to 8 am for calcium oxalate, 2–4 pm 
for uric acid, or any 2-h timed urine collection during day-
time for calcium phosphate [31]. More studies in this direc-
tion are likely to be helpful.
Consensus on Q2
The Consensus Group agreed that 24-h urine analysis is 
essential for diagnosing and following stone patients and 
should be the main modality utilized in most practices. 
However, the Group recognizes the significant value of other 
urine collection modalities and encourages further research 
in this area.
Q3. How many urine collections 
should be made from a given patient 
and how frequently should follow‑up 
urine samples be collected to monitor 
the patient’s progress?
Studies have shown that a single urine collection often does 
not provide a complete picture of the abnormalities in a 
stone patient, and that collection of two urine samples for 
analysis is generally better [32–34]. One practical aspect 
of having at least two analyses is that variations in dietary 
factors can sometimes be easily identified (such as when 
oxalate excretion varies dramatically between two days) and 
identification of relevant conditions such as hypercalciuria 
can be more accurately established [32].
It is also recognised that the diagnostic accuracy of 
24 h-urine testing not only increases with the number of 
urines collected, but also with time passing before urine col-
lections after a stone event, most likely due to a vanishing 
‘stone clinic effect’ [35].
Patient education is also important for proper urine col-
lection, both to motivate the patient to complete the collec-
tions properly and to ensure that the collections represent the 
patient’s normal lifestyle practices. For the two 24-h urine 
samples at initial evaluation, it is wise to coach the patient 
that one collection should be done on a day at work and one 
performed on a non-working day. Left to their own choice, 
a patient is likely to want to collect both specimens at home, 
yet most people spend more days at work than at home and 
the environmental and nutritional differences may be critical 
in determining their stone risk. Most importantly, 24-h urine 
collections should only be carried out when the patients are 
consuming their free, everyday diets—never as in-patients, 
since the foods and drinks served in hospital may be very 
different from those normally consumed by the patients at 
home.
The frequency of follow-up analyses should be deter-
mined by the kind of treatment that has been prescribed, 
but in most cases an initial follow-up at 3–6 months is war-
ranted [36, 37]. If no changes are made in treatment, then 
annual checks thereafter are probably sufficient for tracking.
Consensus on Q3
The Consensus Group recommends two 24-h urine analyses 
for initial evaluation of stone patients. One collection should 
be made on a workday and the other should be made during a 
non-workday. It is important that the patients should collect 
their 24-h urines when they are consuming their free, eve-
ryday diets. Follow-up at 3–6 months is recommended. The 
Consensus Group emphasizes that patient education on how 
and when to collect their 24-h urine samples is important.
Q4. Is urine composition a reliable indicator 
of the patient’s diet?
It is well known that dietary habits affect the risk of kidney 
stone formation. There are a number of ways to assess a 
patient’s diet: (1) diet diary; (2) 24-h diet recall; (3) food 
frequency assessment; and (4) 24-h urine chemistries. These 
approaches have strengths and weaknesses, but the use of 
24-h urine composition in conjunction with one of the diet 
history approaches may provide the most comprehensive 
way to assess the role of diet and its effect on stone risk.
Urine data provide an objective measure that does not 
depend on patient recall (with its possible bias), and the data 
relevant to diet can be interpreted quickly and easily. The 
dietary data derived from the 24-h urine analysis also allow 
assessment of the possible metabolic interaction between 
certain dietary factors that may have an effect on urinary risk 
factors for stones; for example, if the patient has a high urine 
calcium it is important to know if markers of sodium and 
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protein intake are high for the same day [38, 39]. Multiple 
24-h urine collections also provide an estimate of dietary 
variance [34, 40].
Dietary sodium intake is notoriously difficult to estimate 
by history or food frequency questionnaire. Salt added dur-
ing food preparation is often unquantified as is salt added at 
mealtime. Urine sodium excretion is considered the most 
reliable method to assess sodium intake [41]. Confounding 
factors include excessive sweating, diarrheal diseases, and 
sodium retention (such as during menstruation), all of which 
can lead to discrepancy between sodium intake and urine 
sodium excretion, but in general urinary sodium excretion 
is a sufficiently accurate measure of dietary sodium intake 
to be a useful clinical tool [42, 43].
Urine potassium can be used as a marker of dietary potas-
sium intake. Approximately 85 to 90% of diet potassium is 
absorbed assuming normal gut function [42]. In steady state, 
urine potassium excretion will approximate intestinal potas-
sium absorption. Because potassium is predominantly an 
intracellular cation there is considerable capacity to accept 
the dietary load, leading to some offset in time from inges-
tion to excretion of a potassium load. However, there is still 
good agreement of intake to excretion [43]. Urine potassium 
excretion can be particularly useful in monitoring adherence 
to prescribed potassium alkali.
Urine urea can be used as a marker of total protein intake 
[42], while sulphate is as a marker of animal protein intake, 
as sulphur amino acids are oxidized to sulfuric acids, which 
is excreted as sulphate [42, 44]. These two markers are 
highly correlated, and either can be used to monitor protein 
intake. As sulphate is probably not measured routinely in all 
stone clinics, it should be mentioned that uric acid is also a 
reliable marker of animal (non-dairy) protein, because—in 
comparison with other urinary protein markers such as phos-
phate and sulphate—only uric acid increases significantly on 
certain acid-rich diets [45].
Despite these strengths, there are weaknesses in using 
24-h urine data alone to assess diet. This method will yield 
data only for a single day’s diet and will not provide a meas-
ure of fat or carbohydrate intake. Moreover, the urine data 
alone will not allow an assessment of calcium or oxalate 
intake. A further limitation of using the 24-h collection for 
dietary assessment is that it is possible that some patients 
may temporarily increase their compliance with their die-
tary advice in an attempt to “improve” the composition of 
their urine collection, which they can accomplish easily for 
a single day. This applies particularly to the intake of fluid 
and its effect on urine volume. It is recognised that patients 
often try to “please” their doctor by drinking more on the 
day before and during the day of their urine collection. The 
Internet may also play a significant role in directing patients 
(rightly or wrongly) as to what to eat and drink to self-treat 
their stone problem.
In addition to providing a primary therapeutic endpoint 
for solutes, passing a sufficiently large urine volume is 
critical for reducing solute supersaturation levels in stone 
formers. To increase urine volume, fluid intake greater than 
average may not by itself overcome the effects of living or 
working in a high ambient temperature, physical activity or 
chronic diarrhoea [46, 47]. Thus, the patient should achieve 
a goal of urine output rather than a set fluid intake [42] 
and in this regard, the 24-h urine volume is a very useful 
measure.
Urine pH, citrate, calcium and oxalate are dependent on 
factors in addition to diet and, therefore, cannot be used as 
reliable indicators of dietary intake. Citrate and pH depend 
on the balance of alkali intake and intake of dietary acid 
precursors, as well as loss of alkali from the gastrointesti-
nal tract and physiologic abnormalities such as metabolic 
syndrome. Only a fraction of dietary calcium is absorbed, 
and that fraction varies from person to person. Urine cal-
cium may also derive from bone mineral; furthermore, it is 
influenced by sodium and protein intake [48]. All in all, this 
makes calcium intake difficult to assess from urinary excre-
tion alone. Oxalate has variable intestinal absorption and 
50% or more of urine oxalate derives from endogenous oxa-
late production. Moreover, the calcium content of the diet 
itself influences the intestinal absorption of oxalate, prob-
ably because the formation of insoluble calcium oxalate in 
the food mixture reduces the oxalate available for intestinal 
absorption [49–51]. Indeed, a recent paper has demonstrated 
that high calcium ingested simultaneously with food intake 
reduces oxaluria and significantly also urinary CaOx super-
saturation in idiopathic calcium oxalate stone formers [52].
Consensus on Q4
The Consensus Group recognizes that although urine chem-
istry has limitations as an indicator of dietary intake, it nev-
ertheless provides important information about diet that 
cannot be easily obtained by other means, and which can 
be valuable for managing treatment of the individual stone 
former.
Q5. How should urine collections be made—(a) 
in a container which does not contain a preservative 
of any kind, (b) in a container to which preservative 
has been added before collection, (c) in a container 
to which preservative is added after collection or (d) 
some other method of collection?
The addition of stabilizers and the conditions under which 
urine is collected and stored represent important aspects 
to consider in the determination of 24-h urinary constitu-
ents. In most situations, a 24-h urine specimen cannot be 
analysed immediately, and so an additive that will inhibit 
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the growth of microorganisms in the specimen is necessary 
[53, 54]. One approach for this has been to add thymol as 
a preservative to the container before collection (at about 
1 g thymol per litre capacity of the container [54], and this 
method appears to preserve all important urine constituents 
to be measured [55, 56]. Other preservatives (such as chlo-
rhexidine) have also been used [57]. Another approach has 
been to add acid (typically boric acid [1]) to the container 
before collection, as is commonly done for urine collected 
for microbiological analysis [58]. However, if acid is added 
as a preservative, the pH of the urine may need to be meas-
ured in an additional independent specimen, and it should 
be recognized that the pH of a spot urine is unlikely to cor-
respond with that of a 24-h specimen [28].
Consensus on Q5
The Consensus Group agreed that a 24-h urine specimen 
should be collected in the presence of a preservative, and 
that use of a non-acidic preservative simplifies the meas-
urement of all parameters needed for supersaturation 
calculations.
Q6. How should collected urine be handled 
before aliquoting for different analyses?
When a 24-h urine specimen is received (that is preserved 
with a non-acidic agent), its pH should be first measured 
using a pH meter (NOT by dipstick), and then the speci-
men thoroughly mixed. Some reports indicate that urine 
can then be aliquoted for various analyses without any fur-
ther processing [59, 60]. However, studies specifically with 
urine from stone formers have shown that acidification of 
an aliquot is important for proper dissolution of crystals for 
the measurement of calcium and oxalate [61–63], and that 
alkalinisation of another aliquot is important for dissolution 
of uric acid crystals when they are present [63, 64].
Consensus on Q6
The Consensus Group recommends that when a urine speci-
men arrives in the laboratory, its pH should be measured 
immediately using a pH meter. After vigorous agitation, one 
aliquot should be acidified (to pH of < 2) and another alka-
linised (to 6.5 or higher) for dissolution of crystals that may 
be present in the specimen.
Q7. What analytes should be measured in urine 
and why? Should we distinguish between samples 
collected for the routine screening of patients 
and samples collected for specific studies?
The constituents to be measured in a 24-h urine specimen 
are defined by the needs of diagnosing disorders and for 
planning treatment with recurrent stone formers. The volume 
of the 24-h urine specimen is an important measurement, 
and counselling stone formers to increase urine volume is a 
common and effective form of treatment [65]. For analytes, 
pH is essential for the calculation of the relative supersatura-
tion of urine with respect to all potential stone constituents, 
but particularly calcium phosphate and uric acid. It can also 
be an indicator of stone type when its value lies within cer-
tain well-defined ranges. Other urinary constituents which 
the Consensus Group recommends for routine screening are 
calcium, oxalate, citrate and uric acid as they are potential 
indicators of hypercalciuria, mild and hereditary hyperoxalu-
ria, hypocitraturia and hyperuricosuria, respectively, all of 
which are well established risk factors for stone formation. 
Urinary sodium should be measured to assess dietary salt 
intake, as described in question 4 above, and for its potential 
link with hypercalciuria. Additional constituents need to be 
measured particularly for accurate calculation of supersatu-
ration values [66]. These include potassium, magnesium, 
phosphate, chloride, sulphate and ammonium. The latter two 
constituents are also recommended as important markers of 
dietary composition. Creatinine is useful for assessing the 
completeness of a given patient’s 24-h collection, particu-
larly if the patient is being followed up over a period of time. 
Urea is useful for assessing total protein intake, as men-
tioned earlier in this report. Finally, it is recommended that 
cystine screening be performed at least once in each patient 
to rule out this genetic cause of stones, an easy diagnosis 
which is too often neglected [67].
Consensus on Q7
The consensus is that relatively few urinary constituents are 
needed for the routine clinical workup of patients (volume, 
pH, calcium, sodium, oxalate, citrate, uric acid, urea, cre-
atinine) to provide initial insights about possible pathogenic 
conditions and to enable more complete dietary recommen-
dations, but that several more are required to enhance the 
accuracy of supersaturation calculations (potassium, magne-
sium, phosphate, chloride, sulphate and ammonium).
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Q8. What inhibitors and/or promoters 
of crystallization should be measured 
in urine—if any?
The only substances with relative inhibitory capacity that are 
at present routinely determined in urine are citrate and mag-
nesium, and it is likely that the actual effect of these two ions 
is primarily through reduction of supersaturation of calcium 
oxalate and calcium phosphate, rather than through direct 
effects on crystallization [68]. Citrate shows some ability to 
inhibit the crystallization of calcium salts, but probably its 
most important role is related to its ability to form soluble 
complexes with calcium, which results in a decrease in the 
supersaturation levels of insoluble calcium salts [69]. Mag-
nesium, which can also exert a certain capacity to inhibit 
the formation of calcium salts, plays its most important role 
in the formation of a soluble species with the oxalate ion, 
which leads to a decrease in the level of supersaturation of 
urine with respect to calcium oxalate and calcium phosphate 
[68].
It seems certain that macromolecules in urine play an 
important role in the in vitro inhibition and promotion of 
crystallization [70], but there is little understanding of 
which, if any, of these molecules are useful for planning 
treatment in stone formers. Both osteopontin and Tamm-
Horsfall glycoprotein have been shown in laboratory settings 
to inhibit crystallization [71], and excretion of both have 
been found to be lower in stone-formers [72, 73]. However, 
data on how such measurements might be used in governing 
the treatment of stone formers are lacking.
Consensus on Q8
The Group agreed that more research is needed into the 
action of inhibitors and promoters of crystallization in urine, 
and how their concentrations can be clinically managed, 
before measurement of any of these becomes a regular part 
of the screening and treatment of stone formers.
Q9. What are the best methods for analysing 
urine for the analytes specified in Q7?
Most of the constituents to be analysed in urine can be meas-
ured using the methods already established in clinical labo-
ratories but each laboratory should confirm that the preser-
vation method used (e.g., thymol, boric acid, etc.) does not 
interfere with any of the assays performed on the sample. 
Because assays vary in subtle details between manufacturers, 
this issue must be addressed by each individual laboratory.
Standard methods are in place in any clinical laboratory 
for the measurement of volume, pH (by meter, and not by 
test strip or dipstick), calcium, potassium, sodium, mag-
nesium, phosphate, creatinine, urea, chloride. For oxalate, 
either enzymatic or chromatographic methods have been 
shown to work well with urine, but oxalate analysis can be 
especially sensitive to interference by other compounds, 
so laboratories must vet their procedures with care [61, 
74]. It should be noted that to ensure complete dissolution 
of crystals of calcium oxalate in urine, it is essential to 
acidify the aliquot to < pH 2, particularly if the urine has 
both a raised oxalate AND calcium content [57]. However, 
this may raise a problem with the subsequent analysis of 
oxalate in the acidified sample if one of the enzymatic 
methods is used for measuring oxalate. The enzymes con-
cerned work optimally at pH levels approximately between 
3.5 and 5.5. This requires addition of significant amounts 
of alkali to be added to neutralize the added acid with 
a resultant marked increase in the ionic strength of the 
mixture. In turn, this may inhibit the full functioning of 
the enzyme and lead to an underestimate of the oxalate 
content of the urine [75]. Measurement of oxalate is best 
carried out by HPLC [76] or by ion-chromatography [77], 
but attention should be paid to the possibility of high pH in 
the eluent leading to conversion of ascorbic acid to oxalate 
[78]. Citrate can be measured by enzymatic or chromato-
graphic methods [79]. Uric acid is commonly measured 
in automated systems using an enzymatic method [80].
Both ammonium and sulphate (or S) determinations 
are uncommon. Urinary ammonium can be measured by 
enzymatic methods using automated systems [81, 82], and 
the potential exists to use electronic methods [83, 84]. 
For sulphate, either precipitation with barium chloride or 
chromatographic methods is successful [85].
For cystine determination, the colorimetric nitroprus-
side technique works well [86], as do some chromato-
graphic methods [87]. However, analysts should note that 
assays may not distinguish cystine from soluble thiol drug-
cysteine complexes. This would be important in patients 
who are taking tiopronin or D-penicillamine, which form 
thio-cysteine bonds to increase cysteine solubility in urine. 
However, thiol-cysteine bonds can be broken during sam-
ple preparation, releasing cysteine which recombines with 
itself to form cystine. The result is inaccurate measure-
ment in patients taking thiol drugs and inability to judge 
drug efficacy. An approach in managing cystine patients 
and judging the effectiveness of medication has been to 
measure the cystine capacity of the urine, a separate analy-
sis that uses a solid phase method [88, 89]. Newer technol-
ogy may also allow improvements in treatment of cystine 
stones [90].
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Consensus on Q9
The Consensus Group concluded that analysis of most 
analytes needed for proper assessment of 24-h urine col-
lections is standard in most countries. The group agreed 
that more research is needed into the development of an 
easy and fast method for the separate detection in urine 
of soluble and insoluble cystine to monitor treatment in 
patients with cystinuria.
Q10. Are there any specific tests available 
that patients can usefully perform at home 
to assess their risk of forming stones?
Increasing urine volume is a common form of treatment for 
stone patients, and a simple qualitative monitoring of urine 
colour [91] or urine conductivity [92] have been reported 
as being useful to patients who are seeking to maintain an 
appropriate intake of fluids. For some kinds of stones, the 
value of the urine pH is an important indicator of treatment 
success [93] and tracking this through each day using a 
dipstick has been recommended for cystinuric patients [1]. 
New devices that can provide more accurate measurement 
of urine pH by the patient at home are becoming commer-
cially available [94, 95]. Potentially such devices could also 
provide other measures of urine composition.
If such measures are to be employed, it is important to 
counsel the patient on how to carry out the analyses at home 
with proper technique, and for many patients, overcoming 
their reluctance to do anything with their own urine can be a 
challenge. However, research is needed in this area, as there 
is little known about how successful home monitoring of 
urine can be in reducing the rate of stone recurrence.
Consensus on Q10
The Consensus Group accepts that there are tests that 
patients can perform on their own urine at home that may 
be of (minor) utility, but proper counselling of patients is 
essential. However, it is recognized that these tests will 
merely serve as an indicator of progress to the patients them-
selves rather than being of clinical value to the prescribing 
physician. Home monitoring of the urine pH is an impor-
tant measure to self-adjust bicarbonate/citrate treatment in 
cystinuric patients.
Q11. Is there is value in calculating relative 
supersaturation in 24‑h urines?
Urine is said to be supersaturated with respect to a given 
salt or acid when its activity product (a chemical measure 
of how much of a particular salt or acid is contained in a 
solution) exceeds its solubility product at which point the 
urine is said to be completely saturated with the salt or acid 
concerned. When urine is at the solubility product of that 
salt or acid it is defined as having a relative supersaturation 
value of 1. In the case of calcium oxalate, urine from normal 
adults may have relative supersaturation levels between 4 
and 10 [96] but in the urine of untreated stone-formers this 
may reach values of 20 or more [22]. For comparison, the 
relative supersaturation of normal urine with respect to cal-
cium phosphate is in the range 0.4–2.3 [96] but in untreated 
stone-formers may reach values of 10 or more [22]. For uric 
acid, the relative supersaturation of normal urine is in the 
range 0.4–1.9 [96] but in untreated stone-formers may reach 
values up to 3.5 [22].
In general, an increase in the relative supersaturation level 
of any of these salts or uric acid is consistent with the min-
eral deposited in stones [97], and so it makes sense to insti-
tute treatment modalities that are designed to decrease urine 
supersaturation levels in stone-formers. Indeed, reduction in 
the relative supersaturation of urine with respect to calcium 
oxalate correlates with a lower risk for calcium oxalate stone 
recurrence [18].
Measurement of urinary supersaturation of stone-forming 
salts and uric acid has been regarded as the gold standard 
for determining the risk of stone formation for over 50 years. 
Although supersaturation can be determined empirically, 
sophisticated computer programs have been widely used to 
calculate this important urinary property. Examples include 
SUPERSAT [29], EQUIL2 [98], JESS [99], and LithoRisk 
[100]. These programs generate similar but non-identical 
values for supersaturation depending on the number and type 
of urinary constituents that are used in the various calcula-
tions. Lowering mineral supersaturation values by means 
of dietary adjustment or relevant medication has been and 
continues to be the goal of most treatment regimens as it pro-
vides a numerical indication of potential efficacy in reducing 
the likelihood of stone recurrence. Several members of the 
Consensus Group stated that they seek to reduce calcium 
oxalate urine supersaturation levels in the urines of calcium 
oxalate stone formers to half of their initial value, but con-
sensus was not agreed on a definitive target value for this 
objective.
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Consensus on Q11
The Group agreed that calculated relative supersaturation 
values provide a better indication of the propensity for crys-
tals to form than will the measure of any single analyte in 
urine, and that these can be useful in directing treatment 
of stone formers and in assessing the efficacy of treatment.
Q12. Is there any value in using indices 
of stone risk that seek to predict stone 
recurrence?
As discussed above, values for urine supersaturation can 
be useful in identifying urine properties to be targeted for 
therapy (low volume, high calcium, etc.) and for assessing 
the success of therapy (indicated by a reduction in urine 
supersaturation). But other efforts have been made to use 
urine analyses (or other data) to provide prediction of the 
probability of stone recurrence in a given patient, in part to 
reduce the number of analyses necessary for the calculation 
of relative supersaturation using sophisticated computer pro-
grams. These indices also can have the value of integrating 
data in ways that avoid any controversy about cut-off values 
for what would be ‘normal’ in analysis results [16].
The two Tiselius Activity Product (AP) Indices for cal-
culating the risk of forming calcium oxalate and calcium 
phosphate stones are both relatively simple quotients involv-
ing urine constituents that together require only six measure-
ments in urine: pH, calcium, oxalate, citrate, magnesium, 
and volume [21]. High values of these Indices have been 
shown to correlate with stone recurrence [101]. The Robert-
son set of risk indices (PSF) is another alternative for assess-
ing stone risk [102]. Altogether these indices require seven 
urinary measurements for assessing the biochemical risk 
of forming calcium oxalate and calcium phosphate stones, 
but they also calculate the risk of forming uric acid stones. 
These indices correlate with actual stone recurrence [66]. 
The BONN-Risk Index relies on a laboratory estimation of 
the resistance of a urine sample to support the crystallization 
of calcium oxalate [103]. This is a specialized test procedure 
that includes an implicit assessment of the levels of promot-
ers and inhibitors of crystallization in the urine and has been 
claimed to discriminate between a population that was prone 
to form stones and one that was not [104].
None of these measures has become widely adopted 
by physicians treating stone patients, and none has been 
assessed in trials to evaluate how well they can predict stone 
recurrence in a given patient. Yet, each shows promise to be 
able to identify patients who are at risk of stone recurrence.
Consensus on Q12
The Consensus Group recognizes that several urine-based 
risk indices have been proposed, but that as yet none has 
the support of clinical trials to establish any of them as a 
standard predictor of stone recurrence in patients. The Group 
recommends that research in this area would be of great 
value to the stone treatment community.
Q13. How should the results of screening tests be 
reported to the urologist or nephrologist treating 
the patient and how should the results be conveyed 
to the patient in a patient‑friendly format?
The results of 24-h urine measurements can appear as a long 
list of numbers that will be difficult to interpret for the inex-
perienced physician, and incomprehensible to the patient. 
Thus, a simplified graphical format for presenting these data 
can go a long way toward making them broadly useful within 
the stone treatment community. It may also be a valuable 
means to convey in a simple visual way the results of urine 
analysis to the patients concerned.
Two examples of how reports might be presented are 
shown in Fig. 1. The upper panel shows part of a 24-h urine 
analysis report in which the colour of each box in the table 
and the size of typeface draw the eye to values that increase 
the chances of stone formation. If one reads the report from 
bottom-to-top, one sees the progress of the patient over time. 
The lower panel shows another approach, in which risk indi-
ces calculated from urine data are displayed in the form of a 
coloured Target Diagram, where values distant from the cen-
tre (i.e., in the red zone of the target) indicate a higher risk 
for stone recurrence and the values that the patient should 
be targeting to be safe from stone recurrence are shown in 
the central, green bull’s-eye.
These are just two examples, and within our Consensus 
Group, a number of laboratories presently utilize a variety 
of such graphical approaches to enhance readability by the 
physician and to provide effective ways to convey results 
to a patient. Note that both examples in Fig. 1 allow the 
physician to show the patient what changes have occurred 
with alterations in diet or medication. This kind of graphical 
information is likely to improve patient motivation and help 
advance the physician–patient relationship over the course 
of monitoring stone disease within a given individual.
Consensus on Q13
The Group strongly recommends that results of 24-h urine 
analyses should be communicated in a manner that enhances 
understanding in both physician and patient, and that physi-
cians should consider using any of the graphical methods 
which are available.
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Fig. 1  Examples of urine analysis reports that include graphical fea-
tures to aid in interpretation. a Part of the LithoLink report (Labora-
tory Corporation of America, Burlington, NC, USA) for 24-h urine 
results. Note that measures that are out of the normal range are high-
lighted both by a change in background colour and an increase in the 
size and boldness of the typeface. The history of the patient is also 
shown, with the most recent results on the top line. Note that in this 
case, the patient has significantly increased the urine volume, and 
thereby reduced the supersaturation value for calcium oxalate (SS 
CaOx). However, this was done along with a dramatic increase in die-
tary salt (Na 24), which likely led to the increase in urine calcium (Ca 
24), which was part of what drove an increase in the supersaturation 
value for calcium phosphate (SS CaP). b Part of the graphical report 
for urine results from the LITHOSCREEN system for assessing stone 
patients [29]. Note that targeted values (least likely to lead to a stone 
recurrence) are at the centre of the diagram, in the green bull’s eye. 
PSF indicates the Robertson biochemical risk of forming stones as 
described above under Q12. The initial untreated PSF values for the 
patient are shown in the purple lines and shape, and the values after 
treatment are shown in light blue. Before treatment, this patient was 
at risk of forming both uric acid and calcium oxalate stones or a mix-
ture of the two. Following suitable dietary treatment, the PSF values 
of the patient all fell into the green bull’s eye. Similar target diagrams 
are also available for both 24-h urine and dietary composition [29]
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Q14. Is there value in studying crystalluria?
The presence of crystals in urine is prima facie evidence that 
the balance between solute supersaturation and promoters 
on one hand and inhibitors of crystallization on the other has 
tipped toward precipitation. As such, crystalluria can provide 
evidence of the propensity of the urine to form stones [105]. 
However, it is recognized that this is not a conclusive diagnos-
tic as some non-stone formers form crystals in their urine [106, 
107], although these crystals, at least for calcium oxalate, are 
reported to be smaller and less aggregated than those found in 
the fresh urine samples from recurrent stone-formers [108].
Studies of repeated urine specimens for crystalluria have 
shown that this kind of crystalluria (large crystals, aggre-
gated crystals) to be strongly correlated with stone recur-
rence [22, 108]. Furthermore, a more recent study of 188 
patients over 3 years with multiple urine specimens showed 
that having 50% or more urine samples with crystals was 
predictive of stone recurrence with a sensitivity of 88% 
and a specificity of 84% [14]. This study is very suggestive 
that persistent crystalluria accurately reflects a propensity 
for stone formation. Similar results were seen in cystine 
patients, in which the volume of cystine crystals was also 
seen as highly predictive of those patients who would form 
a new cystine stone [109].
Additionally, examination of urine crystals can reveal 
rarer types of stone disease. For example, the crystals of cys-
tine and 2,8-dihydroxyadenine in urine are very distinctive, 
easy to identify under the microscope, and pathognomonic 
of these two genetic diseases [105, 110].
Unfortunately, obtaining the proper urine specimens to 
determine crystalluria requires patients to submit specimens 
early in the morning, and for the specimens to be examined 
promptly (see comments in Q15 below). In addition, labora-
tory personnel must be skilled in assessing urinary crystals 
by microscopic examination. All these issues currently make 
assessment of crystalluria rare.
Consensus on Q14
Crystalluria provides a natural indication of the propensity 
for stone formation, and thus would be valuable in assess-
ing the probability of stone recurrence and in indicating if 
treatment is efficacious. Availability of crystalluria deter-
mination in more laboratories would likely benefit patients 
who are motivated to reduce their risk of stones. However, 
the Consensus Group recognizes that research in this area 
is needed for standardization of results and for the develop-
ment of easy-to-perform evaluation methods (and possibly 
automatization) so that the use of crystalluria in diagnosis 
and treatment can become a routine part of care for stone 
formers.
Q15. How should crystalluria best be 
assessed?
In most laboratories presently assessing crystalluria, it is 
thought that examination of the first morning urine yields 
the most crystals, reflecting the propensity of minerals to 
precipitate in the urine when it is most concentrated. How-
ever, unless the patient lives in close proximity to the analy-
sis laboratory, this is unlikely to be practical. Thus, typical 
analyses are done using the second morning urine, which is 
collected midstream, while on premises at the laboratory, 
and immediately submitted for analysis [111, 112]. Urine 
is kept at room temperature and processed quickly (ideally 
within 20 min, but certainly within 2 h). Urine pH should 
be measured by meter. An aliquot of the urine is centrifuged 
to concentrate the specimen 20-fold, and then 50 µl pipetted 
onto a slide and topped with a coverslip.
These laboratories generally record crystal counts as 
number per high-power field, and crystal types are iden-
tified using a combination of bright-field and polarization 
microscopy [105, 110]. With this method, crystalluria can 
be expressed as mild (1–5 crystals per high power field), 
moderate (6–10), severe (11–20), and very severe (> 20). 
Alternatively, it is possible to quantify crystal content of 
urine using machine measures [108, 113], an approach that 
may be more likely to be automated in a way that assess-
ment of crystalluria could be made more widely available. 
As mentioned above under Q14, the development of auto-
mated evaluation methods for assessing crystalluria would 
be useful, as would be the standardization of criteria for 
measurement and reporting of urinary crystals. Research in 
these areas is needed.
Consensus on Q15
For present practice, the Consensus Group recommends that 
crystalluria should be determined by microscopy in morn-
ing urines by a skilled observer. The Group also recognizes 
that research into new methods, standardization of reporting 
criteria, and further research into how to apply test results 
for patient diagnosis and treatment will all be important for 
making crystalluria determination more widespread in the 
treatment of stone diseases.
Q16. How should kidney stones best be 
analysed?
All published guidelines on treatment of stone form-
ers include stone analysis as a first step in classifying the 
patient. Indeed, assessment of the results from the analysis 
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of urine is impossible to do properly without knowing the 
kind of stone produced.
Stone analysis begins with examination of the stone under 
a stereomicroscope to assess which part (or parts) of the 
stone should be taken for molecular analysis. Most stones 
contain more than one mineral [114], and identification of 
visually distinct parts of the stone for dissection is important 
for correct analysis of minor constituents [115]. Stone por-
tions taken should then be analysed by a molecular method, 
typically by either infrared spectroscopy or X-ray diffraction 
to identify mineral types [116]. Whatever method is used, 
it is important that it be able to distinguish, for example, 
brushite from other forms of calcium phosphate, and cal-
cium oxalate dihydrate from monohydrate.
It is relatively simple to identify the morphological types 
of stones. This can significantly support clinically relevant 
information [117, 118]. This is done during the initial exami-
nation by stereomicroscope and typically also includes vis-
ual examination of the interior of the stone. It is easy, for 
example, to distinguish a calcium oxalate stone that formed 
initially as the dihydrate, which is indicative of the pres-
ence of hypercalciuria [119], even when its composition will 
have transformed over time to the monohydrate form of the 
mineral.
As discussed for the measurement of crystalluria, above, 
it is recognized that the development of methods of stone 
analysis that do not require a skilled observer would be valu-
able in enabling analysis of stone morphology and composi-
tion to be carried out more widely across the globe.
Consensus on Q16
The Consensus Group strongly recommends that stone anal-
ysis be performed if possible as part of the workup of stone 
patients. The analysis should be conducted using infrared 
spectroscopy or X-ray powder diffraction. Visual identifica-
tion of stone morphology is also valuable.
Q17. Is there any value in analysing stone 
fragments?
Analysis of whole stones yields information on morphol-
ogy and composition, but also allows discovery of the man-
ner in which the stone was retained during early growth. 
Specifically, the identification of stones that have grown on 
Randall’s plaque is easy to perform [120]. However, many 
methods of stone removal (e.g., shock wave lithotripsy, laser 
lithotripsy) result in the fragmentation of stones.
Though information of how a stone might have been 
formed (such as the presence of Randall’s plaque) is lost 
when stones are fragmented, analysis of the fragments 
still allows for the mineral composition to be determined. 
Sometimes the general morphological class of the stone can 
also still be identified [117]. A general principle for stone 
analysis is that the more complete the specimen, the better 
will be the quality of the analysis [121], so submission of 
collections of fragments for analysis will generally be better 
than sending just a few.
Consensus on Q17
The Consensus Group recommends the analysis of frag-
ments, because knowledge of a stone’s mineral composition 
(albeit only partial) is an integral part of interpreting 24-h 
urine results and in planning treatment.
Conclusions
The Consensus Group concludes that analyses of urine 
and stones should be routine in the diagnosis and treat-
ment of urinary stone diseases. At present, the 24-h urine 
is the most useful type of urine collection, and methods 
for analysis and standards for interpretation are widely 
available. Patient education is also important for obtaining 
a proper urine sample. Graphical methods for reporting 
urine analysis results can be helpful both for the physician 
and for educating the patient as to proper dietary changes 
that could be beneficial. Proper analysis of stones is also 
essential for diagnosis and management of patients. The 
Consensus Group also agrees that research has shown that 
evaluation of urinary crystals could be very valuable, but 
the Group also recognizes that existing methods for assess-
ment of crystalluria do not allow this to be part of stone 
treatment in many places.
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